Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
OXBDF Quote, Financials, Valuation and Earnings
Last price:
$8.75
Seasonality move
:
5.55%
Day range:
$8.75 - $8.75
52-week range:
$3.15 - $12.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.74x
P/B ratio:
9.28x
Volume:
125
Avg. volume:
8.2K
1-year change:
110.34%
Market cap:
$1.1B
Revenue:
$164.6M
EPS (TTM):
-$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$23.9M | -$0.43 | 205.06% | -3.26% | $8.99 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OXBDF
Oxford Biomedica Plc
|
$8.75 | -- | $1.1B | -- | $0.00 | 0% | 4.74x |
|
AUTL
Autolus Therapeutics Plc
|
$1.63 | $8.99 | $433.8M | -- | $0.00 | 0% | 8.46x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$0.94 | $17.94 | $788.5K | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.13 | $104.00 | $8.9M | -- | $0.00 | 0% | -- |
|
SLNCF
Silence Therapeutics Plc
|
$1.75 | -- | $248M | -- | $0.00 | 0% | 123.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.394 | -- | 1.99x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.062 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.660 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.264 | 0.95% | 4.03x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.663 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Oxford Biomedica Plc vs. Competitors
-
Which has Higher Returns OXBDF or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of -373.3%. Oxford Biomedica Plc's return on equity of -120.93% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital OXBDFOxford Biomedica Plc-- -- $140.3M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About OXBDF or AUTL?
Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $8.99 which suggests that it could grow by 451.53%. Given that Autolus Therapeutics Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Autolus Therapeutics Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings OXBDFOxford Biomedica Plc0 0 0 AUTLAutolus Therapeutics Plc10 0 0 -
Is OXBDF or AUTL More Risky?
Oxford Biomedica Plc has a beta of 1.131, which suggesting that the stock is 13.064% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 1.949, suggesting its more volatile than the S&P 500 by 94.948%.
-
Which is a Better Dividend Stock OXBDF or AUTL?
Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OXBDF or AUTL?
Oxford Biomedica Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Oxford Biomedica Plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.74x versus 8.46x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OXBDFOxford Biomedica Plc4.74x -- -- -- AUTLAutolus Therapeutics Plc8.46x -- $21.1M -$78.6M
-
Which has Higher Returns OXBDF or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of --. Oxford Biomedica Plc's return on equity of -120.93% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital OXBDFOxford Biomedica Plc-- -- $140.3M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About OXBDF or BDRX?
Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 18820.35%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings OXBDFOxford Biomedica Plc0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is OXBDF or BDRX More Risky?
Oxford Biomedica Plc has a beta of 1.131, which suggesting that the stock is 13.064% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.181%.
-
Which is a Better Dividend Stock OXBDF or BDRX?
Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OXBDF or BDRX?
Oxford Biomedica Plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Oxford Biomedica Plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.74x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OXBDFOxford Biomedica Plc4.74x -- -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns OXBDF or NCNA?
NuCana Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of --. Oxford Biomedica Plc's return on equity of -120.93% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital OXBDFOxford Biomedica Plc-- -- $140.3M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About OXBDF or NCNA?
Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 976425.82%. Given that NuCana Plc has higher upside potential than Oxford Biomedica Plc, analysts believe NuCana Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings OXBDFOxford Biomedica Plc0 0 0 NCNANuCana Plc0 1 0 -
Is OXBDF or NCNA More Risky?
Oxford Biomedica Plc has a beta of 1.131, which suggesting that the stock is 13.064% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.688, suggesting its more volatile than the S&P 500 by 68.831%.
-
Which is a Better Dividend Stock OXBDF or NCNA?
Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OXBDF or NCNA?
Oxford Biomedica Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Oxford Biomedica Plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.74x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OXBDFOxford Biomedica Plc4.74x -- -- -- NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns OXBDF or SLNCF?
Silence Therapeutics Plc has a net margin of -- compared to Oxford Biomedica Plc's net margin of -13181.13%. Oxford Biomedica Plc's return on equity of -120.93% beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital OXBDFOxford Biomedica Plc-- -- $140.3M SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About OXBDF or SLNCF?
Oxford Biomedica Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Oxford Biomedica Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Oxford Biomedica Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings OXBDFOxford Biomedica Plc0 0 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is OXBDF or SLNCF More Risky?
Oxford Biomedica Plc has a beta of 1.131, which suggesting that the stock is 13.064% more volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.764, suggesting its less volatile than the S&P 500 by 23.608%.
-
Which is a Better Dividend Stock OXBDF or SLNCF?
Oxford Biomedica Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oxford Biomedica Plc pays -- of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OXBDF or SLNCF?
Oxford Biomedica Plc quarterly revenues are --, which are smaller than Silence Therapeutics Plc quarterly revenues of $159K. Oxford Biomedica Plc's net income of -- is lower than Silence Therapeutics Plc's net income of -$21M. Notably, Oxford Biomedica Plc's price-to-earnings ratio is -- while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oxford Biomedica Plc is 4.74x versus 123.28x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OXBDFOxford Biomedica Plc4.74x -- -- -- SLNCFSilence Therapeutics Plc123.28x -- $159K -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 7.15% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 6.83% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.13% over the past day.
